Last reviewed · How we verify

NCT07105761: BMS

Body-Mind-Spirit Action Group on the Well-being

Completed NA Last updated 13 August 2025
What this trial tests

NA trial testing Body-Mind-Spirit in Quality of Life (QOL) in 36 participants. Completed in 1 July 2024.

Timeline
26 April 2023
Primary endpoint
25 July 2023
1 July 2024

Quick facts

Lead sponsorTaipei City Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designsequential
Maskingnone
Primary purposehealth services research
Enrollment36
Start date26 April 2023
Primary completion25 July 2023
Estimated completion1 July 2024
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Taipei City Hospital

Who can join

Adults 20 to 95, any sex, with Quality of Life (QOL) or Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Primary Purpose: To evaluate the effectiveness of a culturally adapted BMS group intervention on holistic well-being, depressive symptoms, sleep parameters, and quality of life in individuals with visual impairment. Study Objective: This study aims to find out whether a 10-week BMS group program can help people with visual impairment feel emotionally better, improve their overall well-being, enhance sleep quality, and experience a higher quality of life. Intervention Description: The BMS group meets once a week for 10 weeks, with each session lasting about 2 hours. Sessions include guided discussions, storytelling, and experiential activities drawn from both Eastern and Western philosophies. These practices focus on: Appreciating kindness in others Letting go of past hurt (forgiveness) Practicing mindfulness and living in the present moment What the Researchers Want to Know: Does the program help participants feel less depressed? Does it help them feel more balanced, hopeful, and connected in daily life? Does it improve their sleep and overall well-being? Participants: About 30 community-dwelling adults with visual impairment will take part in the study. They will be randomly assigned to one of two groups: The intervention group will join the BMS sessions for 10 weeks. The control group will continue their usual community activities with no new program. All participants will complete surveys at three points: before the program starts, at the midpoint (week 5), and after the program ends (week 10). These surveys assess levels of depression, well-being, sleep quality, and life satisfaction. Some participants in the BMS group will also be invited to join short interviews to share their experiences-such as feeling more grateful, confident, or resilient. Overall Goal: The goal of this study is to determine whether a supportive, culturally adapted group program can help people with vision loss feel stronger, less depressed, more connected, and better equipped to manage their daily lives. Previous findings suggest that BMS group therapy effectively enhances sleep duration and significantly improves quality of life-especially in psychological well-being-among visually impaired individuals. These findings support the integration of BMS therapy into holistic care strategies to promote emotional resilience, well-being, and personal growth in this population.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. A pilot study of body-mind-spirit group therapy on sleep and quality of life in individuals with visual impairment.
    Liu CR, Tseng MY, Sharma D, Hsieh WD, et al · · 2026 · PMID 42070200 · DOI 10.1007/s11136-026-04260-6

Verify or expand the search:

Other recruiting trials for Quality of Life (QOL)

Currently open trials in the same condition.

Other Taipei City Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07105761.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing